Identification of Emerging Multidrug-Resistant Neisseria gonorrhoeae Isolates against Five Major Antimicrobial Agent Options

Med Sci (Basel). 2023 Mar 31;11(2):28. doi: 10.3390/medsci11020028.

Abstract

Antimicrobial drug resistance in Neisseria gonorrhoeae has been documented all over the world. However, the situation in Sub-Saharan Africa has received little attention. It is critical to establish diagnostics and extend surveillance in order to prevent the emergence of illnesses that are resistant to several treatments. Monitoring antimicrobial susceptibility is critically required in order to gather data that may be utilised to produce treatment recommendations that will result in effective therapy, a decrease in gonorrhoeae-related difficulties and transmission, and effective therapy. Government authorities may set research and preventive objectives, as well as treatment recommendations, using data from the Gonococcal Antimicrobial Surveillance Program (GISP). Local and state health authorities may use GISP data to make choices about the allocation of STI prevention services and resources, to guide preventative planning, and to disseminate information about the most successful treatment practices. Using molecular and culture approaches, we investigated the occurrence of antibiotic resistance in isolates from KwaZulu Natal, South Africa. The great majority of gonococcal isolates (48% showed absolute resistance to ciprofloxacin), with penicillin and tetracycline resistance rates of 14% each. Only one of the gonococcal isolates tested positive for azithromycin resistance, with a minimum inhibitory concentration (MIC) of 1.5 µg/mL. Ceftriaxone was effective against all gonococcal isolates tested.

Keywords: N. gonorrhoeae; antibiotics; antimicrobial resistance; minimum inhibitory concentrations; multi-drug resistance; public health.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Anti-Infective Agents* / therapeutic use
  • Ceftriaxone / pharmacology
  • Ceftriaxone / therapeutic use
  • Gonorrhea* / drug therapy
  • Gonorrhea* / epidemiology
  • Humans
  • Neisseria gonorrhoeae

Substances

  • Anti-Bacterial Agents
  • Anti-Infective Agents
  • Ceftriaxone

Grants and funding

The authors acknowledge the National Research Foundation of South Africa (grant number: 112980; 145396) and the South African Medical Research Council through its Division of Research Capacity Development under the Early Investigators Programme awarded to OJP. The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.